Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This
is very difficult to treat and almost all patients will die of their disease within 3 years.
Sunitinib has become standard therapy for untreated patients with metastatic clear cell renal
(kidney) cancer. It targets a growth factor known as VEGF which is important in treating
renal cancer. Although the results with this drug are impressive, patients develop resistance
to the drug, relapse and die of renal cancer. It is currently standard practice is to treat
patients with everolimus when resistance to sunitinib occurs; this is associated with clear
clinical benefit. However the median time to progression with everolimus is 4.9 months in
previously treated patients, therefore further improvement in treating patients is required.
The optimal way of achieving this is to increase the efficacy of everolimus by adding agents
which directly target the cause of resistance to sunitinib.
Dovitinib is a promising new drug in renal cancer. Dovitinib blocks cellular functions such
as activation of downstream signalling molecules, cell proliferation and survival. Combining
dovitinib and everolimus is very attractive.
This trial is aimed to establish the maximum tolerated dose for the combination of dovitinib
and everolimus in clear call renal cancer, which can then be taken into a randomised phase II
study.
A maximum of 30 patients will be recruited into this multi centre national trial.
Expansion Cohort:
The study has established the MAD and the MTD. The MTD was Cohort 0 (Everolimus 5mg and
Dovitinib 200mg). 6 patients were recruited in this cohort with only 1 patient experiencing a
DLT. A further 3 patients were recruited into Cohort 1 (Everolimus 5mg and Dovitinib 300mg),
where 2 patients experienced a DLT.
A total of 7 assessable patients will be recruited during the expansion phase at the MTD
(Cohort 0: Everolimus 5mg and Dovitinib 200mg) to further define the safety, tolerability,
efficacy, PK and biological end points.
Assessable patients for the expansion cohort are defined as being on the study for a minimum
of 6 weeks. Any patients enrolled who are not assessable will be replaced.